Receivables, Loans, Notes Receivable, and Others (Policies)	6 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
Accounts Receivable	Further information regarding the accounting policy for the Facility can be found in Note 3 in the Company's 2023 Form 10-K.As of June 30, 2024, there were $322 million of sold accounts receivable that have not been collected from pharmaceutical manufacturers and have been removed from the Company's Consolidated Balance Sheets. At December 31, 2023, all sold accounts receivable had been collected from pharmaceutical manufacturers. As of June 30, 2024 and December 31, 2023, there were $713 million and $515 million, respectively, of collections from pharmaceutical manufacturers that have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.